Compare peptides side-by-side
Pick any two peptides to compare their evidence quality, FDA approval status, research scores, risks, and indications. All data sourced from the SmartPeptide library.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
CJC-1295 / Ipamorelin
Growth-hormone secretagogue combination studied for stimulating endogenous GH pulses in research contexts.
Full pageBoth compounds have pharmacology data in healthy adults showing increased endogenous GH pulses without affecting prolactin or cortisol much. Some PK/PD trials are published.
Outcome trials (body composition, recovery, longevity) are sparse and mostly small. Long-term safety of repeated GH stimulation is not well established.
Carries risks similar to elevated GH (insulin resistance, edema). Not approved for general use.
Water retention, injection-site irritation, headaches.
GHRP-2
Growth Hormone Releasing Peptide-2. Synthetic hexapeptide ghrelin-receptor agonist. Stimulates GH release potently and consistently. Studied since the 1990s; approved in some Asian markets for diagnostic GH stimulation, NOT for therapeutic use in the US.
Full pageStrong, reproducible GH release in healthy adults; used diagnostically in some countries to assess GH reserve. Body-composition / athletic performance benefits in humans are not established in modern RCTs.
Therapeutic adult use, long-term safety, optimal cycling, combinations with CJC-1295 etc.
Hyperprolactinemia, cortisol elevation, appetite stimulation (notable). Long-term safety in non-diagnostic use is unestablished. Source quality varies dramatically.
Hunger (often pronounced), injection-site reactions, mild flushing, possible nausea, water retention.